prophase financials, page-29

'It is expected that POH will be cash flow positive in about 12 months provided Cellucreme works well.....'

Surely clear enough. POH have bet the house on the launch's success. The differences of opinion reflecting views on the likelihood of success.

It does look quite an optimistic throw, given:-
- the cost of thoese launches, not just upfront but sustained for a period
- POH's quite remarkable lack of human & financial resources in this context
- a product's inherent qualities are only a minor part of the equation, particularly in cosmetics.
- From what has benn reported on the Elixia trial, it was a desperately amateur effort; no doubt they leant a lot, but it does seem to highlight a lack of expertise.

Assuming it goes belly up, there is a saver suggested by Lodge 'and this could be complemented by Oxypatch.'
The Board were reported to be considering a number of options for funding. Fair chance an upfront of some sort would be available - but a company struggling could not expect advantageous terms.

The alternative, given the 'technology' now seems solid, must have been to take the long road, proving OXY, licensing the cosmeceutical side and raising funding as needed - it would surely be readily available. As has been pointed out above re Nestle, there seems to be a romantic urge in Mamagement to go for hype & the quick, spectacular success.

The die is cast, whatever any of us may hope/fear/think. An interesting few months ahead.